Grant Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 13, 2022	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities		$ 68,375		$ 68,375		$ 85,873
Vaccinal Antibody Grant | Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Grant revenue		300	$ 1,600	1,700	$ 3,800
Vaccinal Antibody Grant | Gates Foundation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares purchased (in shares)	881,365
Common stock, shares purchased price (in USD per share)	$ 45.38
Common stock, shares purchased, aggregate purchase price	$ 40,000
Common stock, shares issued, fair market value	$ 28,500
Closing stock price (in USD per share)	$ 37.65
Premium received	$ 11,300
Unused grant funds returned		9,500
Deferred revenue		9,400		9,400		11,100
Accrued and other liabilities		$ 2,100		$ 2,100		$ 11,600